Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Fludarabine Injection Market by Type (25mg/ml, 50mg/2ml), By Application (Hospital, Clinics, Recovery Center) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Fludarabine Injection Market by Type (25mg/ml, 50mg/2ml), By Application (Hospital, Clinics, Recovery Center) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 370448 4200 Pharma & Healthcare 377 193 Pages 4.7 (33)
                                          

Market Overview:


The global fludarabine injection market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of lymphoma and leukemia, rising demand for better treatment options, and growing awareness about available treatment options. Based on type, the global fludarabine injection market is segmented into 25mg/ml and 50mg/2ml. The 25mg/ml segment is expected to account for a larger share of the market than the 50mg/2ml segment during the forecast period. This can be attributed to its lower price point and ease of use. Based on application, the global fludarabine injection market is segmented into hospital, clinics, and recovery center. The hospital segment is expected to account for a larger share of the market than other segments duringthe forecast period owingtoits higher adoption rates due tobetter reimbursement scenarioand availabilityof advanced infrastructure facilities.


Global Fludarabine Injection Industry Outlook


Product Definition:


Fludarabine Injection is a drug used to treat leukemia, lymphoma, and other cancers. It is a type of chemotherapy.


25mg/ml:


Fludara is a type of chemotherapy drug used to treat cancer. It works by stopping the formation of new blood cells which leads to low blood volume. Low blood volume causes side effects such as breathlessness, fatigue and weakness or dizziness among others. Fludara (fludarabine)is an analog of darabine; it is a light yellow crystalline solid that belongs to the family of drugs called fluorouracil derivatives.


50mg/2ml:


50mg/2ml is a generic medicine used for the treatment of chronic myeloid leukemia. It is manufactured by some of the big pharma companies such as GlaxoSmithKline, Bayer Healthcare, and Sanofi Aventis. 50MG/2ML is also known as Fludara or Fludarabine. It has been approved by the U.


Application Insights:


The hospital application segment accounted for the largest share of more than 60.0% in 2017. The increasing number of patients suffering from cancer and a rise in the prevalence rate are some of the factors that drive the demand for fludarabine injection at hospitals. According to data published by WHO, an estimated 962 new cases were registered globally every day in 2018, which includes 729 male and 233 female patients above 50 years of age. This is expected to boost market growth over the forecast period as recovery centers do not have enough capacity to accommodate such a large number of patients due to their limited treatment facilities compared with hospitals thus driving demand for fludarabine injection at clinics & recovery centers over next few years.


Fludara injections are used along with other chemotherapy drugs or alone as second-line therapy after other chemotherapeutic drugs have failed or cannot be used because they affect bone marrow function or cause severe toxicity.


Regional Analysis:


North America dominated the global market in 2017 owing to the presence of key players and high adoption rate of fludarabine. The region is expected to maintain its dominance over the forecast period due to increasing cancer cases, which will boost demand for fludarabine treatment. For instance, according to statistics provided by American Cancer Society in 2018, around 2 million new cases were estimated to be diagnosed in U.S., with more than 600 thousand people dying as a result of it. This data further states that African Americans are at a higher risk of developing this disease compared to other ethnic groups in U.S.


Asia Pacific is anticipated to witness lucrative growth over the coming years owing their large population base.


Growth Factors:


  • Increasing incidence of lymphoma: Lymphoma is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. The National Cancer Institute estimates that there will be about 74,680 new cases of lymphoma diagnosed in the United States in 2018 and around 20,140 people will die from the disease. This number is expected to grow significantly due to increasing aging population and rising awareness about lymphoma diagnosis and treatment options.
  • Availability of novel targeted therapies: The development of novel targeted therapies has revolutionized the treatment landscape for many cancers including lymphomas. These drugs are designed to specifically target cancer cells, leading to improved outcomes compared with traditional chemotherapy regimens. As a result, more patients are now being treated with targeted therapies for their lymphomas, driving demand for Fludarabine Injection products.
  • Growing use in stem cell transplantation: Stem cell transplantation is a potentially curative therapy used to replace damaged or diseased stem cells with healthy ones from a donor source (allogeneic) or self (autologous). Fludarabine Injection is increasingly being used as part of conditioning regimens prior to allogeneic stem cell transplants due its ability to suppress the immune system and prevent graft rejection. This is likely to drive growth in demand for Fludarabine Injection over the forecast period

Scope Of The Report

Report Attributes

Report Details

Report Title

Fludarabine Injection Market Research Report

By Type

25mg/ml, 50mg/2ml

By Application

Hospital, Clinics, Recovery Center

By Companies

Fresenius Kabi, Pfizer, Sagent, Teva, Leucadia, Chongqing Lummy, Cisen Pharmaceutical, Hainan Jinrui Pharmaceutical, Jiangsu Aosaikang Pharm, Shanxi Pude Pharma, Guangdong Lingnan Pharmacy

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

193

Number of Tables & Figures

136

Customization Available

Yes, the report can be customized as per your need.


Global Fludarabine Injection Market Report Segments:

The global Fludarabine Injection market is segmented on the basis of:

Types

25mg/ml, 50mg/2ml

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital, Clinics, Recovery Center

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Fresenius Kabi
  2. Pfizer
  3. Sagent
  4. Teva
  5. Leucadia
  6. Chongqing Lummy
  7. Cisen Pharmaceutical
  8. Hainan Jinrui Pharmaceutical
  9. Jiangsu Aosaikang Pharm
  10. Shanxi Pude Pharma
  11. Guangdong Lingnan Pharmacy

Global Fludarabine Injection Market Overview


Highlights of The Fludarabine Injection Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. 25mg/ml
    2. 50mg/2ml
  1. By Application:

    1. Hospital
    2. Clinics
    3. Recovery Center
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Fludarabine Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Fludarabine Injection Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Fludarabine injection is a medication used to treat cancer. It works by stopping the growth of cancer cells.

Some of the major players in the fludarabine injection market are Fresenius Kabi, Pfizer, Sagent, Teva, Leucadia, Chongqing Lummy, Cisen Pharmaceutical, Hainan Jinrui Pharmaceutical, Jiangsu Aosaikang Pharm, Shanxi Pude Pharma, Guangdong Lingnan Pharmacy.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fludarabine Injection Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Fludarabine Injection Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Fludarabine Injection Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Fludarabine Injection Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Fludarabine Injection Market Size & Forecast, 2020-2028       4.5.1 Fludarabine Injection Market Size and Y-o-Y Growth       4.5.2 Fludarabine Injection Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 25mg/ml
      5.2.2 50mg/2ml
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 Hospital
      6.2.2 Clinics
      6.2.3 Recovery Center
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Fludarabine Injection Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Fludarabine Injection Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 25mg/ml
      9.6.2 50mg/2ml
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 Hospital
      9.10.2 Clinics
      9.10.3 Recovery Center
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 25mg/ml
      10.6.2 50mg/2ml
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 Hospital
      10.10.2 Clinics
      10.10.3 Recovery Center
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 25mg/ml
      11.6.2 50mg/2ml
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 Hospital
      11.10.2 Clinics
      11.10.3 Recovery Center
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 25mg/ml
      12.6.2 50mg/2ml
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 Hospital
      12.10.2 Clinics
      12.10.3 Recovery Center
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 25mg/ml
      13.6.2 50mg/2ml
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 Hospital
      13.10.2 Clinics
      13.10.3 Recovery Center
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Fludarabine Injection Market: Competitive Dashboard
   14.2 Global Fludarabine Injection Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Fresenius Kabi
      14.3.2 Pfizer
      14.3.3 Sagent
      14.3.4 Teva
      14.3.5 Leucadia
      14.3.6 Chongqing Lummy
      14.3.7 Cisen Pharmaceutical
      14.3.8 Hainan Jinrui Pharmaceutical
      14.3.9 Jiangsu Aosaikang Pharm
      14.3.10 Shanxi Pude Pharma
      14.3.11 Guangdong Lingnan Pharmacy

Our Trusted Clients

Contact Us